Biocontainment

Moderna will break ground in mid-2023 on a £150 million complex for the creation of mRNA vaccines and therapeutics in the United Kingdom. Located on the Harwell Campus in Oxfordshire, the Moderna Innovation and Technology Centre (MITC) will comprise two 145,000-sf buildings. The Drug Substance Manufacturing Unit will leverage next-generation automation systems to produce high volumes of vaccine materials, accompanied by an early-stage R&D hub that will support clinical trials.

The Hurley Group has transformed an existing office building in New Haven to create the Elm City Bioscience Center. Designed by Svigals + Partners, the adaptive reuse project offers over 100,000 sf of leasable research space for startup companies. Featuring BSL-1 and BSL-2 environments, the eight-story biotech hub provides lab suites with adjacent work areas, meeting rooms, and break rooms. Advanced mechanical, electrical, and plumbing systems enable the structure’s 12,000-sf floor plates to easily adapt to changing requirements and configurations.

Mispro Biotech Services is building a 10,000-sf contract vivarium in Boston's Seaport District. The state-of-the-art facility will enable life science companies of all sizes to conduct preclinical drug development studies on rodents with the support of Mispro’s husbandry services, technical expertise, and regulatory compliance oversight.

The United States Congress passed Senate Bill 5002 in late 2022 to allow methods other than animal testing to be employed to establish drug efficacy and safety. Dubbed the FDA Modernization Act 2.0, the legislation supports the inclusion of cell-based assays, computer models, and microphysiological systems such as organ chips in preclinical testing operations. The bill also rescinds a stipulation that animal studies must be used when seeking a license for a biological product that is biosimilar or interchangeable with another product.

Pfizer is expanding its Chesterfield campus with the construction of a $60 million addition to support vaccine research and development. Providing leading-edge labs, offices, and support spaces, the three-story, 37,000-sf project will adjoin an existing 261,000-sf facility that opened in 2019. A two-story bridge with a covered plaza will link the completed structure to the rest of the 31-acre site. 

The New York City Economic Development Corporation began construction on the $454 million NYC Public Health Laboratory in June of 2022. Strategically sited adjacent to Harlem Hospital, the 240,000-sf building will provide the Department of Health and Mental Hygiene with sophisticated infrastructure for the detection and mitigation of infectious diseases and pathogens.

Albany College of Pharmacy and Health Sciences has acquired an existing life sciences facility to house the Center for Biopharmaceutical Education and Training. Sited adjacent to the school's campus in Albany, New York, the 154,000-sf structure is uniquely designed for biomedical research with over 60,000 sf of BSL-2 and BSL-3 laboratory space. The five-story building will be renovated to create dedicated gene therapy labs, mammalian cell labs, teaching wet labs, biopharmaceutical pilot plants, and fermentation and downstream processing facilities.

The Sixth Edition of the Biosafety in Microbiological and Biomedical Laboratories (BMBL) manual emphasizes the importance of risk assessment and management, communication among all stakeholders, comprehensive procedures to report accidents and exposures, and a new focus on biocontainment of pathogens affecting agricultural animals. First published in 1984, the BMBL still serves as the cornerstone of biosafety practices for the safe conduct of research throughout the world.

North Carolina State University dedicated the $160.2 million Plant Sciences Building in Raleigh in April of 2022. Designed by Flad Architects, the 185,000-sf facility enables academic, government, and industry researchers to develop innovative solutions for global agricultural challenges.

Southern Research will begin construction in mid-2022 on an $84 million biotechnology center in Birmingham, Ala. Providing crucial biocontainment capacity for the study of infectious diseases, the 80,000-sf building will enhance pandemic preparedness efforts with BSL-3 laboratories spanning 7,500 sf. The five-level project will also include structural biology labs, high-throughput screening facilities, and a STEM education center.

Amgen broke ground in March of 2022 on a $550 million biomanufacturing center in Holly Springs, N.C. Accommodating the company's FleXBatch platform, the project will integrate traditional methods for drug substance production with single-use bioprocessing technologies to create a hybrid facility with unrivaled operational efficiencies. The next-generation plant will manufacture advanced therapeutics for the treatment of cardiovascular disease, cancer, osteoporosis, inflammation, and other conditions.

The University of Wyoming opened the $100 million Science Initiative Building in March of 2022 in Laramie. Designed by GSG Architecture and Perkins&Will, the 153,000-sf structure will enhance interaction among multiple disciplines by collocating researchers into a single complex with shared core facilities. Located on the first floor to mitigate vibration, the Center for Advanced Scientific Instrumentation provides electron microscopes, an X-ray refractometer, a mass spectrometer, and micro CT scanners.

Vibalogics completed construction in December of 2021 on a $150 million virotherapy facility in Boxborough, Mass. Sited on 145 acres, the next-generation manufacturing plant supports commercial production of oncolytic viruses, viral vector vaccines, and viral vector gene therapy products. The highly flexible structure incorporates 2,000-liter bioreactors, multiple cGMP production suites, offices, warehouse space, and labs for research, development, and quality control.

Pfizer opened a $68.5 million clinical manufacturing facility in December of 2021 in Durham. Accommodating the company's BioTherapeutics Pharmaceutical Sciences division, the 85,500-sf project will support the creation of gene therapies for the treatment of hemophilia A, hemophilia B, Duchenne muscular dystrophy, and other diseases. Leveraging single-use bioreactors to enable scalable expansion over time, the structure provides multiple drug substance suites, analytical and microbiology labs, and areas for manufacturing and filling. 

Washington University School of Medicine will break ground in spring of 2022 on a $150 million vertical expansion of the Steven & Susan Lipstein BJC Institute of Health in St. Louis. Designed by Lawrence Group to promote collaboration and discovery, the six-story, 160,000-sf addition will provide 103,000 sf of biomedical research space and a 7,900-sf BSL-3 laboratory for the study of infectious diseases such as SARS-CoV-2 and tuberculosis.